AMA outlines recommendations for FDA oversight of generative AI in medicine
The American Medical Association (AMA) has issued recommendations for the U.S. Food and Drug Administration (FDA) regarding the regulation of generative AI in medical applications. The AMA advocates for a risk-based approach to oversight, aiming to safeguard patient well-being while simultaneously encouraging responsible innovation in the healthcare sector. This initiative seeks to establish clear guidelines for the development and deployment of AI tools in clinical settings.
2 articles from 2 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
2 outlets covered “AMA outlines recommendations for FDA oversight of generative AI in medicine”. All of them report the following:
- AMA outlined a path forward for FDA oversight
- Focus on generative AI in medicine
- Calls for risk-based oversight
- Aims to protect patients
- Supports responsible innovation
Which outlets covered this?
All 2 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.